skip to content »

Pathology & Immunology

Houston, Texas

Pathology and Immunology
Pathology & Immunology
not shown on screen

Sridevi Devaraj, Ph.D., DABCC, FACB







Clinical Chemistry


Area of Interest




Current Position

Director of Chemistry, Toxicology and POCT, Texas Childrens Hospital

Director of the Proteomics/Metabolomics Core, Texas Childrens Microbiome Center

Professor of Pathology & Immunology, Baylor College of Medicine

Professional positions held

Director of Special Chemistry and Toxicology, Department Of Pathology, Co-Director, Translational Technologies Program, Clinical and Translational Science Center, University of California, Davis Medical Center, Sacramento, CA

Associate Professor, Laboratory for Atherosclerosis and Metabolic Research

Assistant Professor, Laboratory for Atherosclerosis and Metabolic Research, Director of Toxicology and Interim Director of Chemistry, Department of Pathology, University of California, Davis Medical Center, Sacramento, CA

Assistant Professor, Division of Clinical Biochemistry and Human Metabolism, Department of Pathology, Scholar, Center for Human Nutrition University of Texas Southwestern Medical Center, Dallas, TX

Instructor, Clinical Chemistry, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX Scholar, Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX

Honors and Award

Academic Senate Travel Award

Outstanding Contributions to Science and Technology Award, Northern California American Association of Clinical Chemistry

Reviewer, NIH CVRS, SBIR/STTR Grants

Reviewer, Special Emphasis Panel, NIDDK

Reviewer, American Heart Association Research Grants

Outstanding Speaker Award-American Association of Clinical Chemistry

Editorial Board, Journal of Clinical Pathology

Memberships on Professional Organizations

Chair Elect Lipids and Lipoprotein Division-AACC National

Member, Division of Clinical and Translational Science, AACC

Representative Publications

  • Devaraj S, Jialal I. "Decreased Endothelial Progenitor Cells in Metabolic Syndrome: An Additional Potential Biomarker for Therapy." Experimental Diabetes Research, 2012 (In Press)
  • Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF III, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Richards JR, Halsted CH. S-adenosylmethionine treatment of alcoholic liver disease: a double-blind, randomized, placebo-controlled trial. Alcohol Clin Exp Res (In press) 2011
  • Yun JM, Jialal I, Chien A, Devaraj S. Resveratrol upregulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J of Nutr Biochem (PMID: 21813271), 2011.
  • Siegel D, Devaraj S, Jialal I. Inflammation, Atherosclerosis and Psoriasis. Clinical Reviews in Allergy and Immunology, (In Press), 2011.
  • Devaraj S, Bremer A, Afify A, Jialal I. Adipose tissue biomarkers in subjects with metabolic syndrome. JCEM (In Press) 2011.
  • Devaraj S, Jialal I, Rockwood J, Zak D. Effect of Orange Juice and Reduced Calorie Orange Beverage Supplementation with and without Plant Phytosterols on Plasma Cytokines and PAI-1 Activity. Clinical Nutrition (PMID: 21477901) 2011.
  • Devaraj S, Tobias P, Jialal I. Knockout of Toll-like Receptor-4 attenuates the Pro-Inflammatory State of Diabetes. Cytokine 55(3):441-5, 2011.
  • Devaraj S, Jialal I. Novel CETP Inhibitors-a promising therapeutic strategy for Dyslipidemia? Metabolic Syndrome and Related Disorders, 9(3):163-5, 2011.
  • Jialal I, Devaraj S, Siegel D. CRP induces hypertension in animal models: homo sapiens says no. Hypertens Res.34(7):801-2, 2011.
  • Devaraj S, Tobias P, Kasinath BS, Ramsamooj R, Afify A, Jialal I. Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol. 31(8):1796-804, 2011.

E-mail this page to a friend